Abstract 2312
Background
MicroRNAs (miRs) are small non-coding RNAs. Circulating miRs in plasma are deregulated in patients with metastatic colorectal cancer (mCRC). The aim was to find prognostic circulating miRs for overall survival (OS) in patients with mCRC treated with chemotherapy and cetuximab.
Methods
A prospective biomarker study was conducted. A full plasma miR-panel was tested with TaqMan Human MicroRNA assay in 151 patients treated with 3rd line irinotecan and cetuximab (Discovery cohort, Biweekly study). Significant miRs were validated with Fluidigm arrays, in 95 patients, treated with 1st line chemotherapy and cetuximab (Validation cohort, NORDIC-7.5 study1). Cox regression analysis was conducted, and multivariate analyses performed with adjustment for sidedness, number of metastatic sites, RAS/BRAF mutation status, age and performance status. Consecutive samples after 3 months of treatment were available for 117 and 86 patients in the discovery and validation cohorts, respectively.
Results
Baseline high expression of miR-1247 in the discovery and validation cohorts, was significantly associated with short OS (hazard ratio [HR]) = 2.33, p = 0.0005) based on the multivariate analysis in the validation cohort. High miR-1290 expression after 3 months was prognostic for short progression free-survival (HR = 1.57, p = 0.0465) in both cohorts. In both cohorts, we found a statistically significant decrease in, miR-1290 (p = 0.0051), miR-200b (p = 0.036), and miR-375 (p = 0.00005), from baseline to 3 month-sample, in patients with partial/complete (n = 78) response compared to patients with progressive disease (n = 72).
Conclusions
High expression of miR-1247 was prognostic for short OS in the multivariate analysis in a discovery and validation cohort of patients treated with chemotherapy and cetuximab in both first and third line. A decrease in miR-1247 and miR-1290 during treatment was associated with favorable response. 1Pfeiffer et al, Clin Colorectal Cancer 2015.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jakob Vasehus Scho.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5472 - Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Camilla Qvortrup
Session: Poster Display session 2
Resources:
Abstract
2037 - Updated survival analysis of the randomized phase III trial comparing S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (SALTO) by the Dutch Colorectal Cancer Group.
Presenter: Johannes Kwakman
Session: Poster Display session 2
Resources:
Abstract
3053 - JFMC51-1702-C7: Phase II study investigating efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients (pts) with metastatic colorectal cancer (mCRC) refractory or intolerant to standard chemotherapies.
Presenter: Keisuke Kazama
Session: Poster Display session 2
Resources:
Abstract
3183 - Bevacizumab plus trifluridine/tipiracil in elderly patients with previously untreated metastatic colorectal cancer (KSCC 1602): A single-arm, Phase 2 study
Presenter: Akitaka Makiyama
Session: Poster Display session 2
Resources:
Abstract
3233 - Biweekly TAS-102 and Bevacizumab as a Third-Line Chemotherapy for metastatic colorectal cancer: A Phase II Multicenter Clinical Trial (TAS-CC4 study)
Presenter: Yoichiro Yoshida
Session: Poster Display session 2
Resources:
Abstract
5907 - Liquid biopsy concordance based on clonality and timing of testing in patients with metastatic colorectal cancer
Presenter: Pashtoon Kasi
Session: Poster Display session 2
Resources:
Abstract
1866 - Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer
Presenter: Emilie Moati
Session: Poster Display session 2
Resources:
Abstract
5602 - Clinical relevance of circulating tumor (ct)DNA genotyping for first line cetuximab-based treatment monitoring in metastatic colorectal cancer (mCRC): a prospective multicentric study
Presenter: JOANA Vidal Barrull
Session: Poster Display session 2
Resources:
Abstract
3182 - Clonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer
Presenter: Beili Wang
Session: Poster Display session 2
Resources:
Abstract
5205 - Immune status of patients with different stages of colorectal cancer with and without circulating tumor cells
Presenter: Anastasia Sitkovskaya
Session: Poster Display session 2
Resources:
Abstract